NCT02024230View on ClinicalTrials.gov

Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation Study (REWRAPS)

PHASE4CompletedINTERVENTIONAL

Enrollment

500

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2022

Conditions

Coronary Artery DiseaseAtrial FibrillationStrokeFetal Blood LossMajor BleedingAll Cause Mortality

Interventions

DRUG

Rivaroxaban or Warfarin

a multi-center, prospective, non-randomized, open-label, physician-initiated interventional allocation study either rivaroxaban or warfarin

Trial Locations (1)

461-0021

Yukio Ozaki, Nagoya

All Listed Sponsors

lead

Fujita Health University

OTHER

NCT02024230 - Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation Study (REWRAPS) | Biotech Hunter | Biotech Hunter